Cosciens Biopharma INC 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
COSCIENS Biopharma Inc. reported a significant net loss for 2025, driven by declining revenues and strategic restructuring, including the wind-down of its biopharmaceutical segment and German subsidiaries.
NASDAQ
COSCIENS Biopharma Inc. reports its annual results, highlighting a strategic shift towards natural-based products while addressing material weaknesses in internal financial controls.
NASDAQ
Aeterna Zentaris files an amendment to its 20-F report, updating leadership details and including new certifications and auditor consents.
NASDAQ
20-F: Aeterna Zentaris Reports Financial Results for Fiscal Year 2023, Outlines Strategic Priorities
Aeterna Zentaris reports its financial results for the fiscal year ended December 31, 2023, and provides an update on its strategic initiatives, including a planned merger with Ceapro.
NASDAQ
20-F/A: Aeterna Zentaris Inc. Files Amendment No. 1 to Form 20-F/A for Fiscal Year Ended December 31, 2022
Aeterna Zentaris Inc. files an amendment to its annual report to correct the financial statement preparation standard reference from Item 17 to Item 18 of Form 20-F.